Trial Profile

Phase-I/II trial for relapsed or refractory AML patients combining cytarabine and mitoxantrone with venetoclax

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 13 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Venetoclax (Primary) ; Cytarabine; Mitoxantrone
Indications Acute myeloid leukaemia
Focus Adverse reactions; Therapeutic Use
Acronyms RELAX

Most Recent Events

12 Dec 2023 updated results from the phase-I and additional patients from the phase-II dose expansion in relapsed or refractory (r/r) AML patients, presented at the 65th American Society of Hematology Annual Meeting and Exposition
13 Sep 2023 Planned End Date changed from 1 Apr 2025 to 1 Aug 2025.
13 Sep 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Oct 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com